Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Status:
Suspended
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib Pilot study of anti-PSMA designer T cells in metastatic prostate cancer.
Subjects will receive escalating doses of T cells, with either low or moderate dose
Interleukin 2. The T cells are collected by pheresis and then genetically modified, and given
in a one time infusion.